IRIS Accounts Production v23.3.0.418 01446695 Board of Directors 6.4.22 5.4.23 5.4.23 0 0 false true false false true false Fair value model iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure014466952022-04-05014466952023-04-05014466952022-04-062023-04-05014466952021-04-05014466952021-04-062022-04-05014466952022-04-0501446695ns16:EnglandWales2022-04-062023-04-0501446695ns15:PoundSterling2022-04-062023-04-0501446695ns11:Director12022-04-062023-04-0501446695ns11:PrivateLimitedCompanyLtd2022-04-062023-04-0501446695ns11:SmallEntities2022-04-062023-04-0501446695ns11:AuditExempt-NoAccountantsReport2022-04-062023-04-0501446695ns11:SmallCompaniesRegimeForDirectorsReport2022-04-062023-04-0501446695ns11:SmallCompaniesRegimeForAccounts2022-04-062023-04-0501446695ns11:FullAccounts2022-04-062023-04-0501446695ns11:EntityNoLongerTradingButTradedInPast2022-04-062023-04-0501446695ns11:Director22022-04-062023-04-0501446695ns11:Director32022-04-062023-04-0501446695ns11:CompanySecretary12022-04-062023-04-0501446695ns11:RegisteredOffice2022-04-062023-04-0501446695ns6:CurrentFinancialInstruments2023-04-0501446695ns6:CurrentFinancialInstruments2022-04-0501446695ns6:ShareCapital2023-04-0501446695ns6:ShareCapital2022-04-0501446695ns6:RevaluationReserve2023-04-0501446695ns6:RevaluationReserve2022-04-0501446695ns6:RetainedEarningsAccumulatedLosses2023-04-0501446695ns6:RetainedEarningsAccumulatedLosses2022-04-0501446695ns6:PlantMachinery2022-04-062023-04-0501446695ns6:PlantMachinery2022-04-0501446695ns6:PlantMachinery2023-04-0501446695ns6:PlantMachinery2022-04-0501446695ns6:WithinOneYearns6:CurrentFinancialInstruments2023-04-0501446695ns6:WithinOneYearns6:CurrentFinancialInstruments2022-04-0501446695ns6:RevaluationReserve2022-04-0501446695ns11:Director112022-04-0501446695ns11:Director112021-04-0501446695ns11:Director112022-04-062023-04-0501446695ns11:Director112021-04-062022-04-0501446695ns11:Director112023-04-0501446695ns11:Director112022-04-05014466953ns11:Director32022-04-05014466953ns11:Director32021-04-05014466953ns11:Director32022-04-062023-04-05014466953ns11:Director32021-04-062022-04-05014466953ns11:Director32023-04-05014466953ns11:Director32022-04-05014466952ns11:Director22022-04-05014466952ns11:Director22021-04-05014466952ns11:Director22022-04-062023-04-05014466952ns11:Director22021-04-062022-04-05014466952ns11:Director22023-04-05014466952ns11:Director22022-04-05
REGISTERED NUMBER: 01446695 (England and Wales)















Unaudited Financial Statements for the Year Ended 5 April 2023

for

Medipharm Limited

Medipharm Limited (Registered number: 01446695)






Contents of the Financial Statements
for the year ended 5 April 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Medipharm Limited

Company Information
for the year ended 5 April 2023







DIRECTORS: Z V Solomon
S P Solomon
J J Solomon





SECRETARY: S P Solomon





REGISTERED OFFICE: 12a Matlock Road
Brighton
East Sussex
BN1 5BF





REGISTERED NUMBER: 01446695 (England and Wales)





ACCOUNTANTS: Shearers
Accountants & Chartered Tax Advisers
30 Brunswick Road
Shoreham-by-Sea
West Sussex
BN43 5WB

Medipharm Limited (Registered number: 01446695)

Balance Sheet
5 April 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 689 152
Investment property 5 1,309,008 1,309,008
1,309,697 1,309,160

CURRENT ASSETS
Debtors 6 192,315 71,625
Cash at bank 44,146 148,707
236,461 220,332
CREDITORS
Amounts falling due within one year 7 30,488 52,632
NET CURRENT ASSETS 205,973 167,700
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,515,670

1,476,860

PROVISIONS FOR LIABILITIES 121,846 121,846
NET ASSETS 1,393,824 1,355,014

CAPITAL AND RESERVES
Called up share capital 100 100
Fair value reserve 8 657,564 657,564
Retained earnings 736,160 697,350
SHAREHOLDERS' FUNDS 1,393,824 1,355,014

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 5 April 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 5 April 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Medipharm Limited (Registered number: 01446695)

Balance Sheet - continued
5 April 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 October 2023 and were signed on its behalf by:





Z V Solomon - Director


Medipharm Limited (Registered number: 01446695)

Notes to the Financial Statements
for the year ended 5 April 2023

1. STATUTORY INFORMATION

Medipharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 15% on reducing balance

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

Medipharm Limited (Registered number: 01446695)

Notes to the Financial Statements - continued
for the year ended 5 April 2023

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 6 April 2022 10,996
Additions 659
At 5 April 2023 11,655
DEPRECIATION
At 6 April 2022 10,844
Charge for year 122
At 5 April 2023 10,966
NET BOOK VALUE
At 5 April 2023 689
At 5 April 2022 152

5. INVESTMENT PROPERTY
Total
£   
FAIR VALUE
At 6 April 2022
and 5 April 2023 1,309,008
NET BOOK VALUE
At 5 April 2023 1,309,008
At 5 April 2022 1,309,008

Fair value at 5 April 2023 is represented by:
£   
Valuation in 1998 28,164
Valuation in 1999 25,000
Valuation in 2000 85,000
Valuation in 2001 180,000
Valuation in 2004 27,500
Valuation in 2017 311,900
Cost 651,444
1,309,008

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors - 995
Other debtors 192,315 70,630
192,315 71,625

Medipharm Limited (Registered number: 01446695)

Notes to the Financial Statements - continued
for the year ended 5 April 2023

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors (2 ) 2,298
Taxation and social security 10,345 15,909
Other creditors 20,145 34,425
30,488 52,632

8. RESERVES
Fair
value
reserve
£   
At 6 April 2022
and 5 April 2023 657,564

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 5 April 2023 and 5 April 2022:

2023 2022
£    £   
Z V Solomon
Balance outstanding at start of year 59,849 (13,175 )
Amounts advanced 48,702 79,908
Amounts repaid (64,887 ) (6,884 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 43,664 59,849

J J Solomon
Balance outstanding at start of year 1,548 3,092
Amounts advanced 1,049 1,458
Amounts repaid (2,399 ) (3,002 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 198 1,548

S P Solomon
Balance outstanding at start of year (3,419 ) (417 )
Amounts repaid (2,397 ) (3,002 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (5,816 ) (3,419 )

10. ULTIMATE CONTROLLING PARTY

The controlling party is Z V Solomon.